A selected ion monitoring method for quantifying simvastatin and its acid form in human plasma, using the ferroceneboronate derivative

Takano, Terukazu; Abe, Shinnosuke; Hata, Shunsuke

doi:10.1002/bms.1200190910

Cited by 42 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, numerous methods for analysis of simvastatin and its metabolites determination in human plasma by HPLC methods with difference detectors (ultraviolet, fluorescence and mass spectrometry) have been published [4][5][6][7][8][9]. In addition, some methods of gas chromatography with mass spectrometry for determination of simvastatin and its metabolites have also been published [10][11]. However, most of these methods are tedious and time consuming, which also considered costly for routine analysis work.…”

Section: Introductionmentioning

confidence: 99%

Method Validation for Analysis of Simvastatin in Human Plasma Using Liquid Chromatography Tandem Mass Spectrometry (LC-MS-MS)

Alakhali¹

2013

JCDR

View full text Add to dashboard Cite

Introduction: The Liquid Chromatography Tandem Mass Spectrometry (LC-MS-MS) for determination simvastatin in human plasma has been developed after extraction by by ethyl acetate and hexane (90/10%, v/v) using lovastatin as internal standard. Material and Methods:The mobile phase consisting of mixture of acetonitrile and water (75/25%, v/v) 500μL/min by separated the solutes on a C18 column. discussion:The lower limit of quantitation of 0.25 ng/mL was achieved when the calibration curve was linear from 0.25-50 ng/mL. The entire run time for analysis was only 6 min. The quantitation in the selective reaction monitoring (SRM) in positive ion mode, the daughter ions m/z 325 for simvastatin and m/z 285 for lovastatin were used. The Parent ions in positive ion mode were m/z 441.3 for simvastatin and m/z 405.1 for lovastatin. The intra-day coefficients of variation were less than 14% while the inter-day coefficients of variation were less than 10%. conclusion:The LC-MS-MS detection is sensitive due to its capability to eliminate interferences from endogenous components.

show abstract

Section: Introductionmentioning

confidence: 99%

Method Validation for Analysis of Simvastatin in Human Plasma Using Liquid Chromatography Tandem Mass Spectrometry (LC-MS-MS)

Alakhali¹

2013

JCDR

View full text Add to dashboard Cite

show abstract

“…There are number of assay methods reported in the literature for simvastatin [18][19][20][21][22][23] and losartan [24][25][26][27] . Spectrophotometric techniques provide practical and significant economic advantages over other methods; therefore, they are a frequent choice for analyses.…”

Section: Resultsmentioning

confidence: 99%

In Vitro Evidences for Simvastatin and Losartan Potassium Interaction and Its in Vivo Implications

Arayne

Sultana

Haroon

et al. 2009

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

In the present paper, we describe the in vitro availability of simvastatin, a potent HMG-CoA reductase inhibitor, in presence of losartan potassium, which is a non-peptide angiotensin II receptor antagonist. These studies were carried out at 37, 48 and 60°C in different pH environments simulating human body compartments. The reactions were studied by UV spectroscopy and the availability of both drugs in presence of each other was determined by deriving a simultaneous equation for two component system through modification of Beer`s law. The interactions were further characterized by IR and H 1 NMR spectroscopic techniques. It was observed that availability of simvastatin in presence of losartan at 37 ºC in simulated gastric juice, at pH 7.4 and pH 9.0 was blocked by losartan through the formation of a charge-transfer complex while the availability of losartan in turn was immensely increased. In pH 4.0 these effects were reversed, availability of simvastatin increased and the availability of losartan was depressed. Similar results were observed at higher temperatures.

show abstract

“…Two GC-MS methods have been reported for quantitation of SV and simvastatin acid (SVA) with (Takano et al, 1990) or without derivatization (Morris et al, 1993;Cai et al, 1999). Several HPLC methods with UV (Carlcucci et al, 1992;Tan et al, 2000) or fluorescence (Ochiai et al, 1997) detection were also reported.…”

Section: Simvastatinmentioning

confidence: 98%

Analysis of five HMG‐CoA reductase inhibitors— atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies

Pasha

Syed

Basha

et al. 2005

Biomedical Chromatography

View full text Add to dashboard Cite

A specific, accurate, precise and reproducible high-performance liquid chromatographic (HPLC) method was developed and validated for the simultaneous quantitation of five 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, viz. atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin, in pharmaceutical formulations and extended the application to in vitro metabolism studies of these statins. Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature. The mobile phase consisted of 0.01 m ammonium acetate (pH 5.0), acetonitrile and methanol. Theophylline was used as an internal standard (IS). The HMG-CoA reductase inhibitors and their metabolites were monitored at a wavelength of 237 nm. Drugs were found to be 89.6-105.6% of their label's claim in the pharmaceutical formulations. For in vitro metabolism studies the reaction mixtures were extracted with simple liquid-liquid extraction using ethyl acetate. Baseline separation of statins and their metabolites along with IS free from endogenous interferences was achieved. Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively. The proposed method is simple, selective and could be applicable for routine analysis of HMG-CoA reductase inhibitors in pharmaceutical preparations as well as in vitro metabolism studies.

show abstract

A selected ion monitoring method for quantifying simvastatin and its acid form in human plasma, using the ferroceneboronate derivative

Cited by 42 publications

References 10 publications

Method Validation for Analysis of Simvastatin in Human Plasma Using Liquid Chromatography Tandem Mass Spectrometry (LC-MS-MS)

Method Validation for Analysis of Simvastatin in Human Plasma Using Liquid Chromatography Tandem Mass Spectrometry (LC-MS-MS)

In Vitro Evidences for Simvastatin and Losartan Potassium Interaction and Its in Vivo Implications

Analysis of five HMG‐CoA reductase inhibitors— atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies

Contact Info

Product

Resources

About